MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
HaYa Therapeutics
HaYa Therapeutics

Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.
We are developing a first-in-class biopharmaceutical therapy to treat heart failure.

Connect with HaYa Therapeutics

2017

2017 Gold Switzerland

Sub industry

Therapeutics (Pharma / Biotech)

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.